Publications

Any
    Any

      5596 Results

      Evaluating the impact of stratification on the power and cross-arm balance of randomized Phase 2 clinical trials

      Authors
      A Moseley;M LeBlanc;B Freidlin;R Shallis;A Zeidan;D Sallman;H Erba;R Little;M Othus
      Journal / Conference
      Clinical Trials 2025;0(0). doi:10.1177/17407745241304065
      Year
      2025
      Research Committee(s)
      Leukemia
      Study Number(s)
      MYELOMATCH

      Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study

      Authors
      S El Kababji;N Mitsakakis;E Jonker;A Beltran-Bless;G Pond;L Vandermeer;D Radhakrishnan;L Mosquera;A Paterson;L Shepherd;B Chen;W Barlow;J Gralow;M Savard;C Fesl;D Hlauschek;M Balic;G Rinnerthaler;R Greil;M Gnant;M Clemons;K El Emam;B Eng
      Journal / Conference
      Journal of Medical Internet Research vol. 27 | e66821
      Year
      2025
      Research Committee(s)
      Breast
      Study Number(s)
      S0307

      Health Care Contact Days for Older Adults Enrolled in Cancer Clinical Trials

      Authors
      A Gupta;C Till;R Vaidya;D Hershman;J Unger
      Journal / Conference
      JAMA Netw Open. Mar 3;8(3):e250778
      Year
      2025
      Research Committee(s)
      Cancer Care Delivery
      PMID
      PMID40080017
      PMC
      PMC11907310

      Bone biomarkers and subsequent survival in men with hormone sensitive prostate cancer: results from the SWOG S1216 phase III trial of androgen deprivation therapy with or without orteronel

      Authors
      P Lara;E Mayerson;E Gertz;C Tangen;A Goldkorn;M Van Loan;M Hussain;S Gupta;J Zhang;M Parikh;P Twardowski;D Quinn;N Vogelzang;I Thompson;N Agarwal
      Journal / Conference
      European Urology Feb;85(2):171-176
      Year
      2024
      Research Committee(s)
      Genitourinary
      PMID
      PMID37085425
      PMC
      PMC10662935
      Study Number(s)
      S1216

      Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

      Authors
      C Gallois;Q Shi;J Meyers;T Iveson;S Alberts;A De Gramont;A Sobrero;D Haller;E Oki;A Shields;R Goldberg;R Kerr;S Lonardi;G Yothers;C Kelly;I Boukovinas;R Labianca;F Sinicrope;I Souglakos;T Yoshino;J Meyerhardt;T Andre;D Papamichael;J Taieb
      Journal / Conference
      Journal of Clinical Oncology Jul 1;42(19):2295-2305
      Year
      2024
      Research Committee(s)
      Gastrointestinal
      PMID
      PMID38547438
      Study Number(s)
      CTSU/C80702

      A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

      Authors
      G Garcia-Manero;N Podoltsev;M Othus;J Pagel;J Radich;M Fang;D Rizzieri;G Marcucci;SA Strickland;MR Litzow;M Savoie;B Medeiros;M Sekeres;TL Lin;G Uy;BL Powell;JE Kolitz;RA Larson;RM Stone;D Claxton;J Essell;S Luger;S Mohan;A Moseley;F Appelbaum;HP Erba
      Journal / Conference
      Leukemia Jan;38(1):58-66
      Year
      2024
      Research Committee(s)
      Leukemia
      PMID
      PMID37935977
      Study Number(s)
      S1203

      Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

      Authors
      S Lerner;D McConkey;C Tangen;JJ Meeks;T Flaig;X Hua;S Daneshmand;A Alva;MS Lucia;D Theodorescu;A Goldkorn;M Milowsky;W Choi;R Bangs;D Gustafson;M Plets;IM Thompson
      Journal / Conference
      Clinical Cancer Research Jan 17;30(2):444-449
      Year
      2024
      Research Committee(s)
      Genitourinary
      PMID
      PMID37966367
      PMC
      PMC10824507
      Study Number(s)
      S1314

      A phase II basket trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia

      Authors
      S Patel;M Othus;Y Chae;M Dennis;S Gordon;D Mutch;W Samlowski;W Robinson;E Sharon;C Ryan;G Lopez;M Plets;C Blanke;R Kurzrock
      Journal / Conference
      Clinical Cancer Research Jan 5;30(1):33-38
      Year
      2024
      Research Committee(s)
      Early Therapeutics and Rare Cancers
      PMID
      PMID37882676
      PMC
      PMC10842092
      Study Number(s)
      S1609

      Predicting clinical outcomes in the S1314-COXEN Trial using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression

      Authors
      B Faltas;Z Bai;M Osman;M Brendel;C Tangen;T Flaig;M Plets;MS Lucia;D Theodorescu;D Gustafson;S Daneshmand;J Meeks;W Choi;C Dinney;O Elemento;S Lerner;D McConkey;F Wang
      Journal / Conference
      ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), oral
      Year
      2024
      Research Committee(s)
      Genitourinary
      Study Number(s)
      S1314

      PAPMET2 A Phase II Randomized Trial of Cabozantinib with or without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma (PRCC): SWOG S2200)

      Authors
      B Maughan;M Plets;Y Ged;C Tangen;U Vaishampayan;S Lerner;S Lerner;I Thompson
      Journal / Conference
      ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), TIPS, poster
      Year
      2024
      Research Committee(s)
      Genitourinary
      Study Number(s)
      S2200